Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with advanced solid tumors or Non-Hodgkin's Lymphoma.
Tumors|Non Hodgkin's Lymphoma
DRUG: MGCD0103
Safety and tolerability, 1 year (anticipated)
Clinical response, 1 year (anticipated)|Pharmacokinetics, 1 year (anticipated)|Pharmacodynamics (histone acetylation; biomarkers), 1 year (anticipated)
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with advanced solid tumors or Non-Hodgkin's Lymphoma.